



Magnetic Resonance Spectroscopy — Revisiting the Imaging Aspects of Brain Tumors

Authors

Kalyani Parida¹, Dvijottam Biswal²

¹Utkal University, S.C.B. Medical College & Hospital, Cuttack, Odisha, India

²S.O.A. University, IMS & SUM Hospital, Bhubaneswar, Odisha, India

ABSTRACT

Imaging still remains one of the powerful and non-invasive tools in the field of medicine and biological research. Over time, various imaging tools continue to develop, especially when it comes to the management of brain tumor patients. This research article summarizes the state-of-the-art Magnetic Resonance Spectroscopy (MRS) applications in the etiology of brain tumors. In this article, we discuss MR imaging as a tool to diagnose patients with different kinds of brain tumors. This article also discusses the application of MR Spectroscopy in delineating the type, nature and stages of different brain tumors with respect to the alteration of chemical thumbprints in brain tumor tissues. We review the importance and applications of MRS in general, imaging sequences and image mapping in the context of different types of brain tumors and its cellular and physiological characteristics. With an aim to study the demographic profiles of tumor patients with brain neoplasms and to correlate our findings of Magnetic Resonance Imaging (MRI) to that of MRS, this article provides a basis for understudying the role of MRS to evaluate the biology of different types of brain tumors.

Keywords- *Magnetic Resonance Spectroscopy, Brain Neoplasm, Imaging.*

Introduction

According to the World Health Organization (WHO), brain tumor is classified into four different grades based on several different factors such as histologic feature, immunolabeling, genetic profiles or the severity of penetration^[1-3]. Even though the tumor types, tumor grades and the volume are difficult to evaluate, according to a report published in 2007, grade-1 tumors are considered as low in penetration and non-aggressive while, grade-4 tumors demonstrate high penetration rate^[4]. When it comes to the clinical management of brain tumor patients, modern diagnostic neuroimaging takes a critical place. Neuroimaging is non-invasive and

offers unique opportunities to study and diagnose different profiles of patients with intracranial brain tumors such as metabolic features, hemodynamic features, and genetic information^[5-7]. From decades, pre-operative evaluation of brain tumors or intra-operative navigation of surgical methods utilizing these imaging tools for a better understanding of the post-operative effect on patients' brain. Moreover, the overall purpose of the diagnostic imaging of patients with suspected intracranial tumors includes but is not limited to detection of the presence of neoplasm, localization and characterization of the extent of the tumor.

MRI technology, initially described by Felix Bloch and Edward Mills Purcell provides one of the best platforms to capture high contrast-high resolution diagnostic images [8]. However, the sensitivity and specificity modalities by which it defines the tumor types and grades have their own limitations. In an attempt to overcome these issues, ongoing investigations on brain tumor imaging invest on clinically proven advanced neuroimaging techniques that can develop, validate and extend the existing imaging technologies. The ongoing investigations also focus on methodologies that highlight the functional and metabolic properties of the tumor. While MRI technology is very appropriate for identifying the correct anatomical position/location of a tumor, in contrary MRS provides a comparative outline of the chemical composition between a normal brains to that tumor compromised brain tissues. Also, unlike MRI where magnetic field and radio waves are used to generate high-resolution images, MRS utilizes a series of consecutive tests that are eventually detected by MRI to determine the chemical composition and/or chemical metabolism of a tumor tissue. Irrespective of these subtle differences between these two technologies, both MRS and MRI are conducted on the same machine and are governed by the same principle of magnetism. Here we will outline the variations in brain neoplasm, nature and different stages of brain tumor and tumor grading by emphasizing MRS technology.

Materials and Methods

Patient details

This study is based on the data obtained from 62 patients with brain tumors and long history of headache and vomiting. Parietal and frontal lobe masses were presented with tingling and paresis of opposite extremity. Posterior fossa tumors were presented with cerebellar impairment like head reeling and ataxia. Acoustic Schwannoma in these patients were diagnosed with hearing loss. With few patients, seizure was also observed. The brain tumor was diagnosed with long-echo multi voxel H-MRS in the department of radio diagnosis and modern imaging facility at the SCB medical college and

hospital, Cuttack. We excluded a total of 12 cases from this study as 3 cases demonstrated under-representation (below 50%) of the neoplastic tissue, 7 cases were with radio surgical management of the neoplasm without any evidence of histological confirmation of the diagnosis, and 2 cases with poor spectral quality because of H-MRS voxel contamination with the sellar bone structure. The metabolic data of remaining 50 patients were considered and analyzed in this study. Out of 50 patients, 30 cases of glioma, 7 cases of meningioma, 5 cases of Schwannoma, 3 cases of medulloblastoma, 2 cases of metastases and 3 post operation cases exhibited residual tumor.

Spectroscopy

Before conducting the spectroscopic examination, consent from each patient was obtained. This study utilized 15 Tesla MRI clinical manager (General electronics, Signa Excite). Multi-voxel spectroscopic examinations were guided by T-weighted or T2 weighted images. Postgadolinium T1 weighted MRI was also used as and when needed in this study.

MRS Setup

Under three-dimensional, control the rectangular H-MRS voxel was placed on the projection of the solid part of the tumor, avoiding it's cystic and necrotic areas. Eight Cc voxel size was used in this study. Possible contamination with the subcutaneous fat, skull and cerebra lventricles was avoided as much as possible. Spatial suppression pulses were applied to the outsides of the voxel to reduce spectral contamination, and global and localized shimming on the water proton and optimization of the water suppression was done. Volume- selected water-suppressed long-echo (TR: 400ms, TE: 144 ms, 128-256 acquisitions) spectra were acquired. In each case the reference spectrum with identical size of the voxel was obtained from the normal appearing white matter of the cerebral hemisphere.

Metabolic profile

Centered at 0.9 and 1.5, metabolite signals from mobile lipids (Lip), lactate (Lac), N- acetylaspartate (NAA), creatine (Cr), and choline-containing compounds (Cho) were obtained with values of 1.3 ppm, 2.02 ppm, 3.03 ppm, and 3.2 ppm respectively. Not all metabolites could be identified in each

individual case. Differentiation of Lip and Lac peaks with same position, was based on the assumption of their different directions on H-MRS with TE 136 ms. Therefore, any upward directed peak located at 1.3 ppm was considered as predominantly Lip, whereas any downward directed one was defined as Lac. Presence of each metabolite peak was initially evaluated qualitatively by visual inspection, and type of the pathological H-MR spectra was determined according to the table provided (table-1). Additionally, the peak intensities of NAA, Cho, and Cr in tumors were obtained. Intensity of NAA, Cho, and lip was normalized to Cr of the normal brain (nCr), and the ratios of NAA/Cho, NAA/Cr, Cho/Cr, Cho/NAA, and Cr/NAA were also calculated.

Age and Sex

This study included 29 males and 21 females with an age range between 5 months and 78 years. The median age was 41 years. Majority of patients were in the age group of 30 to 50 years old.

Table. 1 Peak Metabolite Profile

Type of pathological 1H-MRS spectra	Predominant metabolite peak	Presence of lac peak	Presence of lipid peak
Type IA	NAA	No	No
Type IB	NAA	Yes	No
Type IC	NAA	Not relevant	Yes
Type IIA	Cho	No	No
Type IIB	Cho	Yes	No
Type IIC	Cho	Not relevant	Yes
Type IIIA	Lipid(cho preserve)	Not relevant	Yes
Type IIIB	Lipid(cho reduce)	Not relevant	Yes
Type IIIC	Absence of any	detectable metabolite	peak

Results

Out of 50 case studies, 30 patients were diagnosed with glioma. Again, out of 30 glioma patients, we found 10 cases each of glioma grade II, glioma grade III and Glioblastoma Multiforme (GBM) category. While grade II and grade III gliomas are typically characterized by elevated choline, low lactate, low lipid and a trace amount of NAA and creatine; the myoinositol levels are normally lower in grade III gliomas than grade II gliomas [9]. On contrary, GBM are typically characterized with high level of choline, lipid, lactate and a trace amount of

NAA [9]. Similar to grade III glioma, GBM cases are detected with lower level of myoinositol (Fig. 1).




Fig. 1 Graph showing different metabolite content in different categories of brain tumor patients. Data represents medians with 95% confidence interval

In our study, out of 10 cases of grade II gliomas, 2 cases were ependymoma, 2 cases were CPP, 2 cases were pilocytic astrocytoma, 2 cases showed type IIA spectra, 4 cases showed type IIB spectra, 3 cases showed type IIC spectra with mild elevation of lipid peak. One case showed type IIC spectra with moderate elevation of lipid peak (Fig. 2).

Sometime it gets hard to differentiate a true MRS response to that of false positive or non-response MRS as the enhancement in the signal may be of subtle difference that is hard to distinguish. To overcome this issue, usage of T1 subtraction map is pretty standard in the field. Application of T1 maps reduces the variability in the data and also helps identifying the progression in real time [10]. On the other hand, the source of signal abnormality could be anything from radiation effect to that of post-operative gliosis. A quantitative mapping (here it is called T2) engages analysis of individual voxels relaxation time by acquiring T2-weighted images in order to identify tumors and post-operative outcome more specifically [11,12]. We have frequently used these two techniques while analyzing all our MRS results.




Fig. 2 (A) Graph showing Spectra profile for the four different types of Spectra in all grade-II glioma patients (n=10). (B) T1 and T2-weighted MRS in 10 different grade II glioma cases. (C) Case representation of MRS (Ch/Cr and NAA) in grade-II glioma patients.

In grade III glioma, 2 cases showed type IIA spectra, 5 cases showed type IIB spectra, 2 cases showed type IIC spectra and 1 case showed type IIIA spectra. Type IIIa spectra is another form of choroid plexus carcinoma (Fig. 3). We also observed lower NAA/Cr and NAA/Ch ratio in grade III glioma patients compared to grade II glioma patients (except 2 cases).




Fig. 3 (A) Graph showing Spectra profile for the four different types of Spectra in all grade-III glioma patients (n=10). (B) T1 and T2-weighted MRS in 10 different grade III glioma cases. (C)

Case representation of MRS (Ch/Cr and NAA) in grade-III glioma patients.

In GBM, 2 cases showed type IIB spectra, 3 cases showed type IIC spectra and 5 case showed type IIIA spectra (Fig. 4). It is important to note as presented in Fig. 1 that GBM patients with type IIB and type IIC spectra had higher choline, higher ch/cr ratio, lower NAA/Ch and lower NAA/cr ratio as compared to grade II and grade III glioma patients.




Fig. 4 (A) Graph showing Spectra profile for the three different types of Spectra in all GBM patients (n=10). (B) T1 and T2-weighted MRS in 10 different GBM cases. (C) Case representation of MRS (lactate and lipid) in GBM patients.

In our study, out of 50 cases, 7 cases were of meningioma patients. As shown in Fig. 1, meningioma patients show high level of alanine peak, which could not be detected in our MRS spectra analysis. Meningioma patients were detected with elevated choline level up to 3 times more than a normal brain. We could not detect NAA peak and creatine peak as meningioma is extra axial. Consistent with the previous report, we observed elevated level of lactate and lipid peak in these patients [13 and Fig. 1].

Out of 7 cases, 2 cases showed type IIA spectra, 1 case showed type IIB spectra and type IIIA spectra each, and remaining 3 cases showed type IIC spectra (Fig. 5).




Fig. 5 (A) Graph showing Spectra profile for the four different types of Spectra in meningioma patients (n=7). (B) T1 and T2-weighted MRS in 7 different meningioma patients. (C) Case representation of MRS (Ch/Cr) in meningioma patients.

Like meningioma patients, we detected elevated level of choline and absence of creatine in patients with Acoustic Schwannoma, which represented 10% of total case study (5 patients). Consistent with the previous report, these patients were detected with reduced level of NAA and increased level of lipids [13, Fig. 1]. In this study, Acoustic Schwannoma patients showed only type IIC spectra (Fig. 6).




Fig. 6 (A) Graph showing only Spectrum for Acoustic Schwannoma patients (n=5). (B) T1 and

T2-weighted MRS in 5 different Acoustic Schwannoma patients. (C) Case representation of MRS (lipid) in Acoustic Schwannoma patients.

This study had only 6% patients with medulloblastoma. We could not detect taurine peak, which is a typical feature in this type for brain tumor. Consistent with the previous report, these patients were detected with elevated level of choline and little amount of creatine compared to glioma patients. We also observed higher NAA/Ch level and lower Lac/Ch level than glioma patients. In this study, medulloblastoma patients showed 2 cases of type IIA spectra and only type IIC spectra (Fig. 7).




Fig. 7 (A) Graph showing Spectra profile for the two different types of Spectra in medulloblastoma patients (n=3). (B) T1 and T2-weighted MRS in 7 different meningioma patients. (C) Case representation of MRS (Ch/Cr) in medulloblastoma patients.

We had only few cases (only 4%) of metastases patients. In principle, patients with metastases demonstrate only trace level of NAA (even it is absent sometime), low level of creatine and elevated levels of choline. If for some reason, NAA is detected then it is mostly because of contamination with the surrounding brain tissue.^[14] In our study metastases patients showed only type IIIA spectra (Fig. 8).




Fig. 8 (A) Graph showing only Spectrum for metastases patients (n=5). (B) T1 and T2-weighted MRS in 2 different metastases patients. (C) Case representation of MRS (Choline) in metastases patients.

Discussion

Irrespective of aggressive treatment strategies and significant advance in imaging technologies, careful diagnostic strategy of high-grade glioma patients is still needs improvement. The ability of MRS technology to overcome these issues to some extent made it widely accepted in the field where survival prediction rate of different brain tumor patients became possible. MRS can easily predict survival rate both in adult and infant brain tumors. Recently a series of work has demonstrated this fact [15-18]. The ability of MRS to predict survival has been evaluated in both adult and pediatric brain tumor populations. To this end, a series of papers have recently been evaluated the role of ^1H MRSI in prediction of survival of GBM patients [15-17]. The non-invasive diagnosis plays a pivot role in brain tumor patients and it must be accurate as the overall therapeutic plan is mostly depends upon the histopathological grade of the tumor progression [19-20]. As shown in our study, proton MRS imaging technique definitely helps assisting the surgeons in collecting information on representative samples. MRS is very information in that sense, as surgeons can identify the active tumors easily. Moreover,

having an overview on the aggressive tumor region prior to execute surgical resection helps in planning of targeted radiotherapy if that is something in the to-do list. In addition, MRS image based pre-information also helps in follow up studies of the same patient. However, it is important to keep in mind that multimodality MRI (which includes MRSI) provides additional information that eventually helps in selecting the best and suitable treatment for the patients, as described by Crawford et al., 2009 [16]. In future studies we are planning to include MRSI in all our clinical investigations.

In the study 60% of cases were gliomas which are intra-axial tumors. All glioma patients were showing type II pathological spectra characterized by elevated level of choline, reduced NAA, reduced creatine or preserved creatine. In this study difference between grade II glioma and grade III glioma MRS spectra was the preserved NAA and creatine level in former and reduction in the level in the later and higher myoinositol level in the former than the later. GBM showed type III pathological spectra due to the presence of lipid lactate peak and significant reduction in NAA and creatine level, myoinositol level as well as more increase in choline level. Around 14% cases were meningioma, which are extra axial lesions. In this study meningioma was showing type II pathological spectra. Differentiated from intra axial lesions by significant reduction or absence of NAA and creatine. In addition, myoinositol was absent unlike intra axial lesions. Around 10% cases were schwannoma, an extra axial lesions with significant reduction or absence of NAA, creatine or myoinositol. It is note worthy that schwannoma can be easily differentiated from meningioma with its relatively low choline level and Presence of lipid peak in many cases. All cases were showing type II C pathological spectra. Six percent cases were medulloblastoma and are intra axial lesions. In this study they were showing type II pathologic CII spectra and can be differentiated from gliomas with its marked elevated choline peaks without elevation of lipid lactate peak with marked decreased creatine peak. Four percent cases were metastases and were showing type III A pathologic spectra. Like extra

axial lesions, metastases were showing very low NAA and creatine with elevated choline peak and predominant lipid and lactate peak. Remaining 6% cases were post-operative cases showing elevated choline peak and decreased NAA peak, which suggests a possible residual tumor subtype.

Conclusion

As shown in this study, MRS technique and potential emerging new applications to current MRS base imaging platform has definitely future in advancing accurate diagnosis of tumor status both pre and post treatment. MRS findings should never be used in isolation but interpreted in conjunction with the clinical and imaging findings. This is especially important if the list of possible pathologies for differential diagnosis is wide. As it was shown in the present series there is definite variation of the metabolic patterns in neoplasms with the same histological type, whereas more or less similar neurochemical alterations can be observed in completely different diseases. Introduction of the MR scanners with higher magnetic field strength (3Tesla and more) into clinical practice can improve diagnostic efficacy of both structural and spectroscopic neuroimaging and create new options for their combined use. Even though the application of MRS in diagnosis and evaluation of brain tumors is widely accepted by the community and very well documented, we acknowledge that this technique has not been used routinely as a clinical tool. Further work is required in order to collect and analyze data in more organized and timely manner. In addition to the potential improvement in the technical features, overall standardization of analysis techniques is also required. From our experience, we would like to emphasize a careful and large number patient based trial is needed which will provide an evidence-based medicine using MRS as a tool.

References

1. Zulch KJ. Histological typing of tumours of the central nervous system. Geneva: World Health Organization, 1979.
2. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer 2000; 88: 2887. doi: 10.1002/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F
3. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumours. Brain Pathol 1993; 3: 255-268. doi: 10.1111/j.1750-3639.1993.tb00752.x
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol 2007; 114: 97-109.
5. Cha S. Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 2006; 27: 475-487. doi: 10.1007/s00401-007-0243-4
6. Belden CJ, Valdes PA, Ran C, Pastel DA, Harris BT, Fadul CE, Israel MA, Paulsen K, Roberts DW. Genetics of glioblastoma: a window into its imaging and histopathologic variability. Radiographics 2011; 31: 1717-1740. doi: 10.1148/rg.316115512
7. Bangiyev L, Rossi Espagnet MC, Young R, Shepherd T, Knopp E, Friedman K, Boada F, Fatterpekar GM. Adult brain tumor imaging: state of the art. Semin Roentgenol 2014; 49: 39-52. doi: 10.1053/j.ro.2013.11.001
8. Bloch F. Nuclear Induction. Phys Rev 1946; 70: 460-474. doi: 10.1103/PhysRev.70.460
9. Preul MC, Caramanos Z, Collins DL, Villemure JG, Leblanc R, Olivier A, Pokrupa R, Arnold DL. Accurate non-invasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996; 2: 323-325.
10. Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendsuz M, Buckner J, Chang SM, Prados MD, Pope WB, Sorensen AG, Bent Mvd, Yung WA. Report of the jumpstarting brain tumor drug development coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

- Neuro Oncol. 2014; 16 (Suppl 7): vii36–vii47.
11. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, Motevalibashinaeini K, Mischel PS, Pope WB. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. *J NeuroOncol* 2012; 106: 111–119. doi: 10.1007/s11060-011-0638-x
 12. Ellingson BM, Lai A, Nguyen HN, Nghiemphu PL, Pope WB, Cloughesy TF. Quantification of Nonenhancing tumor burden in gliomas using effective T2 maps derived from dual-Echo turbo spin-Echo MRI. *Clin Cancer Res: Off J Am Assoc Cancer Res.* 2015; 21: 4373–4383.
 13. Bruhn H, Frahm J, Gyngell ML, Merboldt KD, Hänicke W, Sauter R, Hamburger C. Noninvasive differentiation of tumors with use of localized proton MR spectroscopy in vivo Initial experience in patients with cerebral tumors. *Radiology* 1989; 172: 541–548. doi: 10.1148/radiology.172.2.2748837
 14. Castillo M, Kwock L, Mukherji SK. Clinical Applications of proton MR Spectroscopy. *AJNR Am J Neuroradiol* 1996; 17: 1–15.
 15. Saraswathy S, Crawford FW, Lamborn KR, Pirzkall A, Chang S, Cha S, Nelson SJ. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. *J Neurooncol* 2009; 91: 69–81. doi: 10.1007/s11060-008-9685-3
 16. Crawford FW, Khayal IS, McGue C, Saraswathy S, Pirzkall A, Cha S, Lamborn KR, Chang SM, Berger MS, Nelson SJ. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. *J Neurooncol* 2009; 91: 337–351. doi: 10.1007/s11060-008-9719-x
 17. Arslanoglu A, Bonekamp D, Barker PB, Horská A. Quantitative proton MR spectroscopic imaging of the mesial temporal lobe. *J Magn Reson Imaging* 2004; 20: 772–778. doi: 10.1002/jmri.20195
 18. Chan AA, Lau A, Pirzkall A, et al. Proton Magnetic Resonance Spectroscopy Imaging in the Evaluation of Patients Undergoing Gamma Knife Surgery for Grade IV Glioma. *J Neurosurg* 2004; 101: 467–475.
 19. Hermann EJ, Hattingen E, Krauss JK, Marquardt G, Pilatus U, Franz K, Setzer M, Gasser T, Tews DS, Zanella FE, Seifert V, Lanfermann H. Stereotactic biopsy in gliomas guided by 3-tesla 1H– chemical-shift imaging of choline. *Stereotact Funct Neurosurg* 2008; 86: 300–307. doi: 10.1159/000155232
 20. Di Costanzo A, Scarabino T, Trojsi F, Giannatempo GM, Papolizio T, Catapano D, Bonavita S, Maggialelli N, Tosetti M, Salvolini U, d'Angelo VA, Tedeschi G. Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy. *Neuroradiology* 2006; 48: 622–631. doi: 10.1007/s00234-006-0102-3